However, it is now becoming clear, from novel biological evidences, that curative approaches in CML patients resistant to TKIs, have not only to consider BCR-ABL-dependent, but also BCR-ABL-independent mechanisms of resistance (2), with a special focus on leukemia stem cells (LSCs). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.